

Paola Mapelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6597238/publications.pdf>

Version: 2024-02-01

69
papers

1,149
citations

430874

18
h-index

434195

31
g-index

71
all docs

71
docs citations

71
times ranked

1563
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of [¹¹ C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression. <i>Clinical Cancer Research</i> , 2011, 17, 7673-7683.	7.0	107
2	High-grade endometrial cancer: value of [¹⁸ F]FDG PET/CT in preoperative staging. <i>Nuclear Medicine Communications</i> , 2010, 31, 506-512.	1.1	73
3	Predictive value of pre-therapy 18F-FDG PET/CT for the outcome of 18F-FDG PET-guided radiotherapy in patients with head and neck cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 21-31.	6.4	60
4	Imaging biomarkers in prostate cancer: role of PET/CT and MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 644-655.	6.4	57
5	Incidental Finding of Parathyroid Adenoma With ¹¹ C-Choline PET/CT. <i>Clinical Nuclear Medicine</i> , 2012, 37, 593-595.	1.3	54
6	Role of 18F-FDG PET in the management of gestational trophoblastic neoplasia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 505-513.	6.4	48
7	[¹¹ C]Choline Positron Emission Tomography/Computerized Tomography for Early Detection of Prostate Cancer Recurrence in Patients with Low Increasing Prostate Specific Antigen. <i>Journal of Urology</i> , 2013, 189, 105-110.	0.4	42
8	¹¹ C- or ¹⁸ F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 43S-48S.	5.0	42
9	[¹¹ C]Choline PET/CT predicts survival in hormone-naïve prostate cancer patients with biochemical failure after radical prostatectomy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 877-884.	6.4	38
10	Radiation Treatment of Lymph Node Recurrence from Prostate Cancer: Is ¹¹ C-Choline PET/CT Predictive of Survival Outcomes?. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1836-1842.	5.0	35
11	Clinical Translation of a Click-Labeled ¹⁸ F-Octreotate Radioligand for Imaging Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1207-1213.	5.0	35
12	Initial prostate cancer diagnosis and disease staging—the role of choline-PET-CT. <i>Nature Reviews Urology</i> , 2015, 12, 510-518.	3.8	34
13	Dual tracer ⁶⁸ Ga-DOTATOC and 18F-FDG PET/computed tomography radiomics in pancreatic neuroendocrine neoplasms: an endearing tool for preoperative risk assessment. <i>Nuclear Medicine Communications</i> , 2020, 41, 896-905.	1.1	28
14	Evaluation of Prostate Cancer with ¹¹ C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis. <i>Journal of Nuclear Medicine</i> , 2016, 57, 49S-54S.	5.0	25
15	Frequency and significance of physiological versus pathological uptake of ⁶⁸ Ga-DOTATATE in the pancreas. <i>Nuclear Medicine Communications</i> , 2014, 35, 613-619.	1.1	21
16	PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature. <i>Cancers</i> , 2022, 14, 1770.	3.7	21
17	Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 139, 117-124.	4.4	20
18	Dual Tracer ⁶⁸ Ga-DOTATOC and 18F-FDG PET Improve Preoperative Evaluation of Aggressiveness in Resectable Pancreatic Neuroendocrine Neoplasms. <i>Diagnostics</i> , 2021, 11, 192.	2.6	20

#	ARTICLE	IF	CITATIONS
19	Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 1. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 74-79.	4.4	18
20	Combined 68Ga-DOTA-peptides and 18F-FDG PET in the diagnostic work-up of neuroendocrine neoplasms (NEN). <i>Clinical and Translational Imaging</i> , 2019, 7, 181-188.	2.1	18
21	Choline PET/CT features to predict survival outcome in high-risk prostate cancer restaging: a preliminary machine-learning radiomics study. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 66, .	0.7	18
22	Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients. <i>Diagnostics</i> , 2021, 11, 2068.	2.6	17
23	Hybrid PET/MRI in Staging Endometrial Cancer. <i>Clinical Nuclear Medicine</i> , 2022, 47, e221-e229.	1.3	17
24	18F-FDG PET/CT for Early Postradiotherapy Assessment in Solitary Bone Plasmacytomas. <i>Clinical Nuclear Medicine</i> , 2015, 40, e399-e404.	1.3	16
25	State of the art of radiomic analysis in the clinical management of prostate cancer: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103544.	4.4	16
26	11C-choline PET/CT predicts survival in prostate cancer patients with PSA \leq 1 NG/ml. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 921-929.	6.4	14
27	Hypoxia PET imaging beyond 18F-FMISO in patients with high-grade glioma: 18F-FAZA and other hypoxia radiotracers. <i>Clinical and Translational Imaging</i> , 2020, 8, 11-20.	2.1	14
28	PET/MRI and prostate cancer. <i>Clinical and Translational Imaging</i> , 2016, 4, 473-485.	2.1	13
29	18F-FAZA PET/CT Hypoxia Imaging of High-Grade Glioma Before and After Radiotherapy. <i>Clinical Nuclear Medicine</i> , 2017, 42, e525-e526.	1.3	13
30	68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in Recurrent Prostate Cancer: Diagnostic Performance and Association with Clinical and Histopathological Data. <i>Cancers</i> , 2022, 14, 334.	3.7	13
31	Epigenetic changes in gastroenteropancreatic neuroendocrine tumours. <i>Oncogene</i> , 2015, 34, 4439-4447.	5.9	12
32	PET/MRI in gynecological tumors. <i>Clinical and Translational Imaging</i> , 2016, 4, 211-220.	2.1	12
33	18F-FAZA PET imaging in tumor hypoxia: A focus on high-grade glioma. <i>International Journal of Biological Markers</i> , 2020, 35, 42-46.	1.8	12
34	The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 554-560.	6.4	10
35	Hypoxia 18F-FAZA PET/CT imaging in lung cancer and high-grade glioma: open issues in clinical application. <i>Clinical and Translational Imaging</i> , 2017, 5, 389-397.	2.1	9
36	PET imaging for lymph node dissection in prostate cancer. <i>World Journal of Urology</i> , 2017, 35, 507-515.	2.2	9

#	ARTICLE	IF	CITATIONS
37	Erdheim-Chester Disease. <i>Clinical Nuclear Medicine</i> , 2011, 36, 704-706.	1.3	8
38	FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2071-2078.	6.4	8
39	Synergic role of preoperative 18F-fluorodeoxyglucose PET and MRI parameters in predicting histopathological features of endometrial cancer. <i>Nuclear Medicine Communications</i> , 2020, 41, 1073-1080.	1.1	8
40	The Role of Positron Emission Tomography/Computed Tomography (PET/CT) for Staging and Disease Response Assessment in Localized and Locally Advanced Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 4155.	3.7	8
41	Unusual presentation of sarcoid-like reaction on bone marrow level associated with mediastinal lymphadenopathy on 18F-FDG-PET/CT resembling an early recurrence of Hodgkin's Lymphoma. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2012, 31, 207-209.	0.0	7
42	Concomitant Lung Cancer and Gastrointestinal Stromal Tumor. <i>Clinical Nuclear Medicine</i> , 2017, 42, e349-e351.	1.3	7
43	18F-FAZA PET/CT in the Preoperative Evaluation of NSCLC: Comparison with 18F-FDG and Immunohistochemistry. <i>Current Radiopharmaceuticals</i> , 2018, 11, 50-57.	0.8	7
44	PET/MRI in Neuroendocrine Tumours: Blessings and Curses. <i>Current Radiopharmaceuticals</i> , 2019, 12, 96-97.	0.8	7
45	[¹⁸ F]fluorodeoxyglucose positron emission tomography/computed tomography and trophoblastic disease: the gynecologist perspective. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 60, 103-116.	0.7	7
46	Sarcoidosis mimicking metastatic gynaecological malignancies: A diagnostic and therapeutic challenge?. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2013, 32, 314-317.	0.0	6
47	Prostate cancer recurrence: can PSA guide imaging?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1781-1783.	6.4	6
48	PET guidance in prostate cancer radiotherapy: Quantitative imaging to predict response and guide treatment. <i>Physica Medica</i> , 2016, 32, 452-458.	0.7	6
49	18F-FAZA PET/CT in pretreatment assessment of hypoxic status in high-grade glioma: correlation with hypoxia immunohistochemical biomarkers. <i>Nuclear Medicine Communications</i> , 2021, 42, 763-771.	1.1	6
50	Función pronóstica de los parámetros derivados de FDG PET en la estadificación preoperatoria del cáncer de endometrio. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2019, 38, 3-9.	0.0	5
51	11C-Choline PET/CT based Helical Tomotherapy as Treatment Approach for Bone Metastases in Recurrent Prostate Cancer Patients. <i>Current Radiopharmaceuticals</i> , 2017, 10, 195-202.	0.8	5
52	18F-FDG PET/CT May Predict Tumor Type and Risk Score in Gestational Trophoblastic Disease. <i>Clinical Nuclear Medicine</i> , 2022, Publish Ahead of Print, .	1.3	5
53	Decoding the Heterogeneity of Malignant Gliomas by PET and MRI for Spatial Habitat Analysis of Hypoxia, Perfusion, and Diffusion Imaging: A Preliminary Study. <i>Frontiers in Neuroscience</i> , 0, 16, .	2.8	5
54	68Ga-DOTA-peptides PET/MRI in pancreatico-duodenal neuroendocrine tumours: a flash pictorial essay on assets and lacks. <i>Clinical and Translational Imaging</i> , 2019, 7, 363-371.	2.1	4

#	ARTICLE	IF	CITATIONS
55	Hybrid cardiac PET/MR: the value of multiparametric assessment in cardiac sarcoidosis. <i>Clinical and Translational Imaging</i> , 2019, 7, 317-326.	2.1	4
56	18F-FDG PET/MRI in endometrial cancer: systematic review and meta-analysis. <i>Clinical and Translational Imaging</i> , 0, , 1.	2.1	4
57	Reply to the letter "Choline PET/CT compared with bone scintigraphy in the detection of bone metastases in prostate cancer patients". <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 912-913.	6.4	3
58	FDG-PET/CT Predicts Outcome in Oropharyngeal Carcinoma Patients Undergoing Intensity Modulated Radiation Therapy with Dose Escalation to FDG-avid Tumour Volumes. <i>Current Radiopharmaceuticals</i> , 2017, 10, 102-110.	0.8	3
59	Evaluation of 18F-fluorothymidine positron emission tomography ([18F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer. <i>EJNMMI Research</i> , 2016, 6, 81.	2.5	2
60	Spinal cord involvement secondary to non-Hodgkin's lymphoma identified by 18F-FDG PET/CT. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2013, 32, 125.	0.0	1
61	The relationship between local recurrences and distant metastases in prostate cancer: can 11C-choline PET/CT contribute to understand the link?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 962-969.	6.4	1
62	Molecular Imaging and Theranostics in Pancreatic Neuroendocrine Tumours: From a Luminous Present to an Even Brighter Future. <i>Current Radiopharmaceuticals</i> , 2019, 12, 93-95.	0.8	1
63	Early variation of 18-fluorine-labelled fluorodeoxyglucose PET-derived parameters after chemoradiotherapy as predictors of survival in locally advanced pancreatic carcinoma patients. <i>Nuclear Medicine Communications</i> , 2019, 40, 1072-1080.	1.1	1
64	Hypoxia and Amino Acid Imaging of High-Grade Glioma. <i>Clinical Nuclear Medicine</i> , 2020, 45, e290-e293.	1.3	1
65	Clinical implication of multimodality imaging of aortic root intramural hematoma. <i>International Journal of Cardiovascular Imaging</i> , 2022, 38, 489-490.	1.5	1
66	Detection of Bone Metastases and Evaluation of Therapy Response in Prostate Cancer Patients by Radiolabelled Choline PET/CT. , 2017, , 75-85.		1
67	Clinical PET imaging of tumour hypoxia in lung cancer. <i>Clinical and Translational Imaging</i> , 2017, 5, 427-445.	2.1	0
68	PO-0886: Early changes of FDG-PET markers predict the outcome after chemo-radiotherapy for pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2017, 123, S486-S487.	0.6	0
69	Negative 11C-choline PET/computed tomography imaging in restaging of patients with prostate cancer with serum prostate-specific antigen values >20â€%ng/mL. <i>Nuclear Medicine Communications</i> , 2020, 41, 1178-1182.	1.1	0